Nova Eye Medical

US Demand And China Approval Will Boost Vision Care Access

AnalystConsensusTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

16 May 25

Updated

15 Aug 25

AnalystConsensusTarget's Fair Value

AU$0.37

61.2% undervalued

15 Aug

AU$0.14

-37.0%

Author's Valuation

AU$0.4

61.2% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

AU$0.4

61.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

25.79%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.26%

Calculation

AU$4.28m

Earnings '28

24.83x

PE Ratio '28

AU$106.37m

Market Cap '28

AU$106.37m

Market Cap '28

230.95m

No. shares '28

AU$0.46

Share Price '28

AU$0.46 Share Price '28

Discounted to 2025 @ 7.25% p.a.

AU$0.37

Fair Value '25